Rapid development of atypical fibroxanthoma during vismodegib treatment

Giorgini, Chiara; Barbaccia, Vincenzo; Croci, Giorgio Alberto; Imarisio, Ilaria; Vassallo, Camilla

doi:10.1111/ced.13736

Search citation statements

Order By: Relevance

Paper Sections

Select...

Hh Pathway In Bcc1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2019

2022

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…26 Additionally, atypical fibroxanthoma was observed in an 83-year-old patient after 30 days of treatment with vismodegib for multiple BCCs. 27 The development of other secondary malignancies, such as squamous cell carcinoma, melanoma, keratoacanthomas, and pilomatricomas, during or after the long-term use of vismodegib also have been described. [28][29][30][31][32][33][34][35]…”

Section: Hh Pathway In Bccmentioning

confidence: 99%

Vismodegib for Basal Cell Carcinoma and Beyond: What Dermatologists Need to Know

Alkeraye¹

2022

Cutis

View full text Add to dashboard Cite

The recommended dosage of vismodegib is 150 mg/d until unendurable side effects develop or disease progression occurs.• The efficacy of vismodegib in the management of locally advanced basal cell carcinoma (BCC) and metastatic BCC is promising. Thus, it is now considered an effective substitute to surgical therapy.• Patients using vismodegib must be closely monitored, as it is commonly associated with adverse events.

show abstract

Section: Hh Pathway In Bccmentioning

confidence: 99%

Vismodegib for Basal Cell Carcinoma and Beyond: What Dermatologists Need to Know

Alkeraye¹

2022

Cutis

View full text Add to dashboard Cite

show abstract

“…AFX usually appears on the skin chronically exposed to sunlight, mostly in elderly males [4]. There are reports of AFX occurring in a burn scar [5] and in patients in course of cancer treatment with Sonic Hedgehog pathway inhibitors [6]. It may seem that risk factors for the tumour are similar to those for squamous cell carcinoma.…”

mentioning

confidence: 99%